Gene Editing Market

Gene Editing Market Overview

The global Gene Editing Market size was valued at USD 6.99 billion in 2024 and is predicted to reach USD 17.79 billion by 2030 with a CAGR of 16.9% from 2025-2030.

Gene editing market is driven by various factors such as increasing genetic disease, expanding agriculture industry and advancement in CRISPR-Cas9 technology. The market is restrained by the high initial cost. Conversely, the development in CRISPR technology indicates future direction and growth prospects. Along with it, some of the major players such as Merck KGaA, Thermo Fishers Scientific Inc., and Pairwise Plants, LLC are following various strategies such as collaboration and acquisition in order to fuel innovation within the domain and retain their leadership in the market.

Rising Genetic Disease Fuels Market Growth

Rising genetic diseases such as sickle cell anemia and cystic fibrosis affect a number of human body organs primarily the lungs and the digestive system and requires genetic mutation treatments. There are about 100,000 people with cystic fibrosis globally according to the American Lungs Association report of 2024. With such rise in the cases of cystic fibrosis globally, the demand for gene editing treatments surges because of its potential to change and replace faulty genes.

Growing Agriculture Sector Bolster Market Growth

Growing agriculture sector globally bolster the industry growth by increasing the need for enhanced crop yields, improved disease resistance, and enhanced nutritional content. Such demand is met by gene editing technologies that enable precise modification of genomes, allowing for creation of more productive crops. According to the report published by the United Nations, the global population is expected to rise to 9.6 billion people by 2050. The growing demand for food supply prompts agricultural companies to invest in gene modification research and development to improve crop yields ultimately boosting the market.

Advancement in CRISPR-Cas9 Spurs Market Trends

The advances in CRISPR-Cas9 technology enable scientists to make actual modifications in an organism's DNA and make gene modification more precise, efficient, and affordable. For example, in December 2023, Food and Drug Administration (FDA) approved Casgevy, a cell-based gene therapy utilising CRISPR-Cas9, a type of genome editing technology to treat sickle cell disease. The development fosters market innovation among key players to innovate and launch their product, thus promoting market growth.

High Upfront Cost Hinders Market Demand

The expense of using gene editing technologies impedes market growth by constricting usage and adoption, particularly for minor research centers and low-income countries. It also delays the progress of innovation, limit the range of gene modification treatments to only a few patients, and end up limiting the general growth of the genome editing market.

Integration of AI in Gene Editing Creates Future Opportunities

Integration of artificial intelligence (AI) in genome editing is anticipated to create ample number of future opportunities. AI’s integration with CRISPR, improves the overall genome editing pipeline by providing new insights, capabilities, and opportunities for manipulating and understanding the genetic code. For instance, in April 2024, Berkeley, California, startup Profluent demonstrated the use of AI for gene editing in a project. Such development promotes research in the domain and creates future scope for the gene modification industry.

Market Segmentations and Scope of the Study 

The gene editing market report is segmented on the basis of product and service, gene editing technology, gene editing approach, gene delivery method, gene delivery modality, type of therapy, mode, application, end-users and region. On the basis of product and services, the market is grouped into reagents and consumables, systems and software, and services. On the basis of gene editing technology, the market is divided into CRISPR, ZFN, antisense, mega nucleases, and other technologies. On the basis of gene editing approach, the market is segmented into gene knock-out and gene knock-in. On the basis of gene delivery method, the market is segregated into ex-vivo and in-vivo. On the basis of gene delivery modality, the market is grouped into viral vectors and non-viral vectors. 

On the basis of therapy, the market is classified into cell therapies, gene therapies, and other therapies. On the basis of mode, the market is divided into in-house and contract. On the basis of application, the market is grouped into genetic engineering and clinical applications. Based on genetic engineering, the market is further grouped into cell line engineering, animal genetic engineering, plant genetic engineering, and others. Based on clinical applications, the market is further segmented into diagnostics and therapy development. On the basis of end-users, the market is segregated into biotechnology and pharmaceutical companies, academic and government research institutes, contract research organizations, and others. Regional breakdown and analysis of each of the aforesaid segments includes regions comprising of North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis

North America region is dominant in the gene editing market share and it is forecasted to hold the same position in coming year due to the rising numbers of genetic disorders such as cystic fibrosis and sickle cell anemia that requires early detection and genetic mutation treatments. According to the American Lungs Association's publication, roughly 40000 people in the U.S. have cystic fibrosis by 2024. With such rise in the cases of cystic fibrosis, the requirement for effective treatment such as gene modification grows significantly in this region due to its potential to slow down, reverse and correct such genetic mutations. 

Also, the market growth is also driven by the growing aging population in the region that fuels age-related conditions as such disorders involve changes in gene expression, thereby boosting the market growth. According to the report of Pan American Health Organisation in 2022, the population aged 60 years and more in Mexico in 2022 is estimated to be 15.12 million while this figure is estimated to increase to 31.50 million by 2050 with a rise of 108%. The growing aging population creates greater pool for gene modification therapies and drives research and innovation that fuels the market growth. 

On the other hand, Asia-Pacific shows a steady growth in the domain and is forecasted to maintain its position in the coming years due to the presence of key player such as GenScript Biotech Corporation and JW Therapeutics that are constantly innovating and unveiling new products. For instance, in June 2024, GenScript Biotech Corporation introduced the FLASH Gene service to address the urgent demand for delivering gene constructs with speed, quality and efficiency. The development reflects the company's attempt to develop gene synthesis services and speed up research activities in the creation of gene and cell therapies. 

Furthermore, the sector is also driven by governmental efforts to establish the biopharma industry in the region that fosters research and development capability as well as export. For instance, in February 2023, the Korean government initiated programs for the development of the bio-health markets. With such expansion, biopharmaceutical companies equip their portfolios with more effective and efficient drugs to realize greater efficacy, and mitigate side effects, thus fueling the industry's expansion.

Competitive Landscape

Various market players operating in the biotechnology market are Merck KGaA, Thermo Fishers Scientific Inc., GenScript Biotech Corporation, Agilent Technologies, PerkinElmer, Lonza Group Ltd., Tecan Life Science, Sangamo Therapeutics, Inc., Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics AG, Beam Therapeutics Inc., Verve Therapeutics, Inc., New England Biolabs, Inc., Pairwise Plants, LLC. These market players are adopting various strategies such as collaborations and acquisition to remain dominant in the market. 

For instance, in September 2024, Pairwise Plants LLC collaborated with Corteva, Inc. to accelerate the delivery of advanced gene editing solutions to farmers. The partnership focuses on accessing agricultural innovation to drive value creation. 

Additionally, in May 2024, Merck acquired Mirus Bio to enhance its capacity in producing viral vectors, essential for creating treatments such as gene therapies. This acquisition encourages Merck's existing capabilities in developing and manufacturing these innovative therapies. 

Moreover, in January 2024, Thermo Fisher Scientific collaborated with Galapagos to provide cancer gene therapy, manufacturing and kitting services in the San Francisco. The aim is to create a network for making CAR-T cell therapies in different locations around San Francisco.

Key Benefits

• The report provides quantitative analysis and estimations of the gene therapy from 2025 to 2030, which assists in identifying the prevailing industry opportunities.

• The study comprises a deep-dive analysis of the current and future gene editing market trends to depict prevalent investment pockets in the industry.

• Information related to key drivers, restraints, and opportunities and their impact on the gene editing market trend is provided in the report. 

• Competitive analysis of the key players, along with their market share is provided in the report.

• SWOT analysis and Porters Five Forces model is elaborated on the study.

• Value chain analysis in the market study provides a clear picture of roles of stakeholders.

Gene Editing Market Key Segments

By Product & Services 

• Reagents & Consumable

• Systems & Software

• Services 

By Gene Editing Technology

• CRISPR

• TALEN

• ZFN

• Antisense

• Meganucleases

• Other Technologies 

By Gene Editing Approach

• Gene Knock-out

• Gene Knock-in

By Gene Delivery Method

• Ex-Vivo

• In-Vivo

By Gene Delivery Modality

• Viral Vectors

• Non-Viral Vectors

By Type of Therapy

• Cell Therapies

• Gene Therapies

• Other Therapies

By Mode

• Contract

• In-House

By Application

• Genetic Engineering

  • Cell Line Engineering 

  • Animal Genetic Engineering 

  • Plant Genetic Engineering 

  • Others

• Clinical Applications

  • Diagnostics

  • Therapy Development

By End Users

• Biotechnology and pharmaceutical companies

• Academic and government research institutes

• Contract research organizations

• Others

By Region

• North America

  • The U.S.

  • Canada

  • Mexico

• Europe

  • The UK

  • Germany

  • France        

  • Italy        

  • Spain        

  • Denmark        

  • Netherlands        

  • Finland        

  • Sweden        

  • Norway        

  • Russia

  • Rest of Europe

• Asia-Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Indonesia

  • Singapore

  • Taiwan

  • Thailand

  • Rest of Asia Pacific 

• RoW

  • Latin America

  • Middle East 

  • Africa

Key Players

• Merck KGaA

• Thermo Fishers Scientific Inc.

• GenScript Biotech Corporation

• Agilent Technologies

• PerkinElmer

• Lonza Group Ltd.

• Tecan Life Science

• Sangamo Therapeutics, Inc.

• Editas Medicine

• Intellia Therapeutics, Inc.

• CRISPR Therapeutics AG

• Beam Therapeutics Inc.

• Verve Therapeutics, Inc.

• New England Biolabs, Inc.

• Pairwise Plants, LLC

REPORT SCOPE AND SEGMENTATION:

Parameters	Details
Market Size in 2024	USD 6.99 billion
Revenue Forecast in 2030	USD 17.79 billion
Growth Rate	CAGR of 16.9% from 2024 to 2030
Analysis Period	2024–2030
Base Year Considered	2024
Forecast Period	2025–2030
Market Size Estimation	Billion (USD)
Growth Factors	Increasing genetic diseases worldwide drives the gene editing market. Growing agricultural sector fuels the market. Improvement in gene editing technologies drives the market.
Countries Covered	28
Companies Profiled	15
Market Share	Available for 10 companies
Customization Scope	Free customization (equivalent to up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.